Omeprazole and misoprostol for preventing gastric mucosa effects caused by indomethacin and celecoxib in rats

Acta Cirurgica Brasileira

Volumn 21, Issue 3, 2006, Pages 168-176

  Cavallini, Míriam Elias ^a,c   Andreollo, Nelson Adami ^b   Metze, Konradin ^b   Araújo, Marina Raquel ^b  

^a Piracicaba Methodist University   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c NONE   (Brazil)

Author keywords

Anti inflammatory agents; Gastric mucosa; Non steroidal; Pharmacology; Stomach

Indexed keywords

CELECOXIB; INDOMETACIN; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; EDEMA; FOOD INTAKE; MEDICAL ASSESSMENT; MEDICAL RESEARCH; MICROSCOPY; NONHUMAN; RAT; STOMACH MUCOSA INJURY; TABLET;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; GASTRIC MUCOSA; INDOMETHACIN; MALE; MISOPROSTOL; OMEPRAZOLE; PYRAZOLES; RATS; RATS, WISTAR; STOMACH ULCER; SULFONAMIDES;

EID: 33744917241     PISSN: 01028650     EISSN: 16782674     Source Type: Journal    
DOI: 10.1590/S0102-86502006000300009     Document Type: Article

References (33)

1. Bateman DN. NSAID'S: Time to re-evaluate gut toxicity. Lancet. 1994; 343: 1051-2.
2. Paulus HE. FDS Artthritis Advisory Committee meeting: postmarketing surveillance of nonsteroidal antiinflammatory drugs. Arthritis Rheumatol. 1985;28:1168-9.
3. Schneider EL. Aging in the third millennium. Science. 1999; 283:796-7.
4. Schmassmann A. Mechanisms of ulcer healing and effects of nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104:43S-51S.
5. Griffin Mr . Epidemiology of nonsteroidal antiinflammatory drug- associated gastrointestinal injury. Am J Med. 1998;104(suppl.1):23S-29S.
6. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol. 1991; 18(suppl. 28): 6-10.
7. Vreeburg EN, Snel P, De Brujine JW. Acute upper gastrointestinal bleeding in the Amsterdam area : Incidence, diagnosis, and clinical outcome. Am J Gastroenterol. 1997; 92:236-43.
8. Segal, WN, Cello JP. Hemorrhage in the upper gastrointestinal tract in the older patient. Am J Gastroenterol. 1997; 92: 42-6.
9. Mccarthy DM . Nonsteroidal antiinflammatory drug induced ulcers : management by traditional therapies. Gastroenterology. 1989; 96:662-74.
10. Barrison I . Prophylaxis against non-steroidal induced upper gastrointestinal side effects. Ann Rheumatol Dis. 1991; 50: 207-9.
11. Brunton LL. Fármacos para controle da acidez gástrica e tratamento de úlceras pépticas. In: Goodman LS, Gilman A, Hardman JG. As bases farmacológicas da terapêutica. 9.ed. Rio de Janeiro: Mc Graw Hill; 1996. p. 663-74.
12. Smith WL. Prostanoid biosynthesis and mechanism of action. Am J Physiol. 1992; 268:181-91.
13. Borda IT, Koff RS. Nsaids. A profile of adverse effects. Philadelphia: Hanley and Belfus Inc; 1992.
14. Gabriel SE, Jaakkirnainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal antiinflammatory drugs: a meta-analysis. Ann Intern Med. 1991; 115 (suppl.1): 787-96.
15. Whelton A. Renal aspects of treatment with conventional nonsteroidal anti - inflammatory drugs versus cyclooxygenase - 2 specific inhibitors. Am J Med. 2001; 110:33S-42S.
16. Takagi K, Okabe S, Saziki, R. A new method for the production of chronic gastric ulcer in rats and the effect of several drugs on its healing. Jpn Pharmacol. 1969;19:418-26.
17. Conover WJ. Practical nonparametric statistics. New York: John Wiley & Sons; 1971.
18. Bralow SP. Experimental gastric carcinogenesis. Digestion. 1972; 5: 290-310.
19. Silen W. Experimental models of gastric ulceration and injury. Am Phys Soc. 1998;24:395G-402G.
20. Okabe S, Amagase K. An overview of acetic acid ulcer models - the history and state of the art of peptic ulcer research. Biol Pharmacol Bull. 2005; (8):1321-41.
21. Brooks P. Use and benefits of nonsteroidal antiinflammatory drugs. Am J Med. 1998; 104(suppl.1):43S-51S.
22. Cheer SM, Goa Kl. Parecoxib (parecoxib sodium). Drugs. 2001;61:1133-41.
23. Chan CC, Boyce S, Brideau C. Rofecoxib (VioX.MK-0966,4- (4 methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone): a potent and orally active cyclooxygenase-2 inhibitor-pharmacological and biochemical profiles. J Pharmacol Exp Ther. 1999; 290(suppl.1): 551-60.
24. Silverstein FE, Faich G, Goldstein JL . Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumathoid arthritis. J Am Med Assoc. 2000;284:1247-55.
25. Cannon GW, Breedveld Fc. Efficacy of cyclooxygenase-2 specific inhibitors. Am J Med. 2001;110(suppl.1):6S-12S.
26. Jonsson B, Wahlqvist P. Management of nonsteroidal anti-inflammatory drug-associated lesions: a cost-effectiveness perspective. Am J Med. 1998;104(suppl.1):81S-8S.
27. Mctavish D, Buckley MM, Heel RC. Omeprazole: an updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs. 1991;42:138-70.
28. Laudanno OM, Esnarriaga J M, Cesolari JA, Maglione CB, Aramberry LJ, Sambrano JS, Piombo G, Rista L. Celecoxib vs indomethacin and acute gastric lesions in rats. Medicina. 2000;60(2):221-4.
29. Coppelli G, Guaita E, Spaggiari S, Coruzzi G. Gastric effects of the selective cyclooxygenase-2 inhibitor, celecoxib, in the rat. Dig Liver Dis. 2004;36(4):265-70.
30. Collins PW. Misoprostol: discovery, development, and clinical applications. Med Res Rev. 1990; 10:149-72.
31. Hawkey CJ . Progress in prophylaxis against nonsteroidal anti- inflammatory drug-associated ulcers and erosions. Am J Med. 1998; 3A(104): 67S-74S.
32. Yeomans Nd. New data on healing of nonsteroidal antiinflammatory drug-associated ulcers and erosions. Am J Med. 1998; 104:56S-61S.
33. Topaloglu U, Muftuoglu T, Akturk Z, Ekinci H, Peker O, Unalmiser S. Omeprazole is more effective than famotidine for preventing acute gastritis in rats. Surg Today. 2004;34(8):690-4.